Two CME presentations and a lunch symposium will feature the world’s first implantable shock absorber (ISA) for knee osteoarthritis FREMONT, Calif.--(BUSINESS WIRE)--Moximed, a medical device company ...
FREMONT, Calif.--(BUSINESS WIRE)--Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that the U.S. Food and Drug ...
Credit: Getty Images. The device is implanted subcutaneously during an outpatient-compatible procedure. The Food and Drug Administration (FDA) has cleared the MISHA ™ Knee System for the treatment of ...
The FDA has authorized marketing of an implantable shock absorber aimed at load reduction for people with refractory knee osteoarthritis (OA) who are not appropriate candidates for arthroplasty, the ...
The U.S. FDA has granted de novo authorization to Moximed Inc. for its Misha knee system, a first-of-its-kind implantable shock absorber for people suffering from osteoarthritis (OA) of the knee. The ...
Please provide your email address to receive an email when new articles are posted on . Moximed received FDA marketing authorization of its Misha knee system. The system is designed for patients with ...
Moximed has announced the treatment of the first subject in the multi-centre MOTION randomised controlled trial (RCT) assessing its MISHA knee system against non-surgical treatment in individuals with ...
The U.S. FDA has granted de novo authorization to Moximed Inc. for its Misha knee system, a first-of-its-kind implantable shock absorber for people suffering from osteoarthritis (OA) of the knee. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback